Prognosis
Covid Shot Derived From Tobacco-Like Plant Tested in Humans
- Medicago launches shot into phase 1 trial with GlaxoSmithKline
- Biotechs look to validate new technologies amid the pandemic
This article is for subscribers only.
Medicago Inc. has been using plants to develop potential vaccines for more than two decades. A new partnership with GlaxoSmithKline Plc. putting its unproven technology to the test against the novel coronavirus is pushing the Canadian biotech into the limelight.
The Quebec City-based company dosed the first humans with its experimental Covid-19 vaccine on Monday, making it one of 23 candidates that have reached phase 1 clinical trials in the race to curb the pandemic, according to the World Health Organization.